C84.76 Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes

Name of the Condition

• Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes (ICD-10 Code: C84.76)

Summary

Anaplastic large cell lymphoma (ALCL), ALK-negative, intrapelvic lymph nodes, is a rare type of non-Hodgkin lymphoma originating from T-cells or null cells. It is characterized by large, abnormal lymphoid cells and typically presents as a systemic disease, though cutaneous involvement may occur. The condition is aggressive and requires prompt evaluation and management.

Causes

The exact cause of ALK-negative ALCL is not fully understood. It is believed to involve genetic mutations in lymphoid cells, which lead to uncontrolled growth and accumulation. Environmental factors or chronic antigen stimulation may contribute to its development, though specific triggers remain unclear.

Risk Factors

• Age: More common in adults, particularly those over 60.
• Immunosuppression: Conditions or treatments that weaken the immune system.
• Genetic predispositions: Family history of lymphoma or related disorders.
• Prior lymphoid disorders: History of other lymphoid malignancies may increase risk.

Symptoms

• Swollen lymph nodes or masses in affected areas.
• Fever, night sweats, and unexplained weight loss (B symptoms).
• Skin lesions, rashes, or nodules (if cutaneous involvement is present).
• Fatigue, loss of appetite, and general malaise.
• Organ-specific symptoms (e.g., abdominal or pelvic discomfort if intrapelvic nodes are involved).

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., CT or MRI), and biopsy of affected lymph nodes. Histopathological examination confirms the presence of large, abnormal lymphoid cells, and immunohistochemistry helps distinguish ALK-negative ALCL from other lymphomas. Staging may include additional tests to assess disease extent.

Treatment Options

Treatment typically involves systemic therapy, such as chemotherapy, targeted therapy, or immunotherapy, depending on disease stage and patient factors. Radiation therapy may be used for localized disease. Clinical trials or novel therapies may be considered for refractory cases.

Prognosis and Follow-Up

Prognosis varies based on disease stage, response to treatment, and patient health. Regular follow-up with imaging and clinical assessments is essential to monitor for recurrence or progression. Long-term surveillance is recommended due to the risk of relapse.

Complications

• Disease progression or recurrence.
• Treatment-related side effects (e.g., infection, organ toxicity).
• Metastasis to other lymph nodes or organs.
• Secondary malignancies (rare).

Lifestyle & Prevention

• Maintain a healthy immune system through balanced nutrition and regular exercise.
• Avoid known immunosuppressive factors (e.g., smoking, excessive alcohol).
• Follow recommended cancer screening guidelines for early detection of related conditions.

When to Seek Professional Help

Seek medical attention for persistent symptoms like unexplained weight loss, fever, night sweats, or swollen lymph nodes. Prompt evaluation is critical for early diagnosis and management.

Tips for Medical Coders

• Use C84.76 for anaplastic large cell lymphoma, ALK-negative, specifically involving intrapelvic lymph nodes.
• Ensure documentation supports the anatomical site (intrapelvic lymph nodes) to justify code assignment.
• Verify that ALK-negative status is confirmed, as this distinguishes it from ALK-positive variants.
• Avoid using this code for cutaneous or unspecified site involvement; select the appropriate code for those scenarios.